This paper presented the new developments on the using deep belief network and computational methods to improve opioid receptor biological activity prediction, novel agonists and antagonists, structural modeling in recent years.
INTRODUCTION
Despite progress in computer modeling, most biological processes are still out of reach. Simpler machine learning approaches might offer superior results, all of the techniques may play a promising role for developing smarter post-operative pain management strategies. The essence of the flexibility properties of MOR can be captured with simple models at different spatial resolutions, opening the way to mechanical approaches to understanding GPCR functions. Deep belief networks, trained with greedy learning algorithms, showed superior performance in prediction over the simple feedback network architectures( NNs). All atom structure, residue interaction network and coarse-grained elastic network models of the μ opioid receptor (MOR). Analyzing of drug design for a selection of G protein-coupled neuro-receptors using neural network techniques, and deep belief networks trained on drug-molecule structures were demonstrated as powerful computational tools, able to aid in drug-design in a fast and cheap fashion, compared to conventional pharmacological techniques. 
Computational Methods to Predict Opioid Receptor Biological Activity
Thousands of molecules and descriptors are available for a medicinal chemist thanks to the technological advancements in different branches of chemistry. This fact as well as the correlation between them has raised new problems in quantitative structure activity relationship studies. Proper parameter initialization in statistical modeling has merged as another challenge recently. Random selection of parameters leads to the performance of deep neural network (DNN). In one research, deep belief network (DBN) was applied to initialize DNNs. DBN is composed of some stacks of restricted Boltzmann machine, an energy-based method which requires computing log likelihood gradient for all samples. Three different sampling approaches were suggested to solve this gradient [1] . In this respect, the impact of DBN was applied based on the different sampling approaches mentioned above to initialize the DNN architecture in predicting targets biological activity that contain more than many molecules. The same as other fields of processing research, the outputs of these models demonstrated significant superiority to that of DNN with random parameters. Deep belief networks trained on drug-molecule structures were demonstrated as powerful computational tools, able to aid in drug-design in a fast and cheap fashion, compared to conventional pharmacological techniques.
The μ opioid receptor (MOR) is a prominent member of the G protein-coupled receptor(GPCR) family and the molecular target of morphine and other opioid drugs. G-protein-coupled receptors (GPCRs) play essential roles in various physiological processes, and are widely targeted by pharmaceutical drugs. There have been presented that the study involving the computational design, expression and characterization of water-soluble variant of a human GPCR, the human mu opioid receptor (MOR), which is involved in pain and addiction. Despite their importance, researching on GPCRs has been problematic due to difficulties in isolating large quantities of these membrane proteins in forms that retain their ligand binding capabilities. Creating water-soluble variants of GPCRs by mutating the exterior, transmembrane residues provides a potential method to overcome all these difficulties. An atomistic structure of the transmembrane domain was built using comparative (homology) modeling and known GPCR structures. The designed variant expressed in high yield in Escherichia coli and was water soluble. The variant shared structural and functionally related features with the native human MOR [2] , including helical secondary structure and comparable affinity for the antagonist naltrexone . The roles of cholesterol and disulfide bonds on the stability of the receptor variant were also investigated. The study exemplifies the potential of the computational approach to produce water-soluble variants of GPCRs amenable for structural and functionally related characterization in aqueous solution.
It could be described that recent developments in the prediction of 3D structures of both α-helical MPs as well as β-barrels using comparative modeling techniques, new methods, and molecular dynamics (MD) simulations. The increase of MP structures has facilitated comparative modeling due to the availability of more and better templates, and improved the statistics for knowledge-based scoring functions. Moreover, new methods have benefited from the use of correlated mutations as restraints. The determination of membrane protein (MP) structures has always trailed that of soluble proteins due to difficulties in their overexpression, reconstitution into membrane mimetics, and subsequent structure determination. The percentage of MP structures in the protein databank (PDB) has been at a constant 1-2% for the last decade. In contrast, over half of all drugs target MPs, only highlighting how little now we understand about drug-specific effects in the human body. To reduce the gap, researchers have attempted to predict structural features of MPs even before the first structure was experimentally elucidated. One review presented current computational methods to predict MP structure, starting with secondary structure prediction, prediction of trans-membrane spans and topology. Even though these methods generate reliable predictions, challenges such as predicting kinks or precise beginnings and ends of secondary structure elements are still waiting to be addressed.
Mu Opioid Receptor(MOR) Agonists And Antagonists
The mu opioid receptor (MOR) is a clinically important G protein-coupled receptor that couples to Gi/o proteins and arrestins. At present, the receptor conformational changes that occur following agonist binding and activation are poorly understood. One study has employed molecular dynamics simulations to investigate the binding mode and receptor conformational changes induced by structurally similar opioid ligands of widely differing intrinsic agonist efficacy, norbuprenorphine, buprenorphine, and diprenorphine. Kappa-opioid agonists are particularly efficacious in the treatment of peripheral pain but suffer from central nervous system (CNS)-mediated effects that limit their development [3] . The five compounds were further screened for specificity of activation of kappa receptors as well as agonism and antagonism at mu and delta receptors, which can lead to offtarget effects.
It can be suggested that important molecular interactions, which active molecules share and distinguish agonists and antagonists. The results allowed for the generation of theoretically validated in silico workflows that were employed for prospective virtual screening. It was also indicated that the antagonism by naloxone at the delta-and kappa-opioid receptors was weaker than that of naloxone at the muopioid receptor. It could be concluded that various sigma ligands directly interact with the cloned mu-, delta-and kappa-opioid receptors in Xenopus oocytes. The results suggest that the effects of the sigma ligands may be partly mediated by the opioid receptors.
Molecular dynamics simulations revealed that these ligands adopt distinct binding poses and engage different subsets of residues, despite sharing a common morphinan scaffold. With the resolved crystal structure of the β-funaltrexamine-MOR complex, research aimed at the discovery of novel agonists and antagonists using virtual screening tools, i.e. docking, pharmacophore-and shape-based modeling.
Mu receptor agonists and agonist-antagonists have been used throughout recent medical history for the control of pain and for the treatment of opiate induced side effects and even opiate withdrawal syndromes. Mu agonists have been an important component of pain treatment for thousands of years. The usual pharmacokinetic parameters (half-life, clearance, volume of distribution) of opioids have been known for some time. A number of opioids are available for clinical use, including morphine, hydromorphone, levorphanol, oxycodone, and fentanyl. However, the metabolism has, until recently, been poorly understood, and there has been recent interest in the role of metabolites in modifying the pharmacodynamic response in patients, in both analgesia and adverse effects [4] . Advantages and disadvantages of various opioids in the management of chronic pain are discussed. One review looks at the structure, chemistry, and metabolism of opioids in an effort to better understand the side effects, drug interactions, and the individual responses of patients receiving opioids for the treatment of intractable pain.
Mμ Opioid Receptor (MOR) Structure-function Relationships
Despite the long tradition of MOR-targeting drugs, still little is known about the ligand-receptor interactions and structure-function relationships underlying the distinct biological effects upon receptor activation or inhibition. Recently, Many studies have demonstrated the existence of a biased agonism for OR at different signaling events including desensitization, phosphorylation, endocytosis, trafficking, and in vivo effects. A new notion has emerged from pharmacological studies of GPCR, called biased agonism or functional selectivity. The binding of different ligands of a single receptor results in distinct conformational changes of receptor; each conformation preferentially interacts with selective partners producing specific signaling cascades [5] . One could trace back the first data on biased agonism for OR when some authors demonstrated that different ligands for the same OR activate different subsets of Gαi/o proteins. The new identified chemotypes hold promise for further development into neurochemical tools for studying the MOR or as potential therapeutic lead candidates. A study is presented on how well possible drugmolecules can be predicted with respect to their function and binding to a selection of neuro-receptors by the use of artificial neural networks. The ligands investigated in this study are chosen to be corresponding to the G protein-coupled receptors µ-opioid.
Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signaling through the β-arrestin pathway or by actions at other receptors. Conversely, G-protein μOR signaling is thought to confer analgesia. Research computationally dock over 3 million molecules against the μOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment. PZM21 thus serves as both a probe to disentangle μOR signaling and a therapeutic lead that is devoid of many of the side effects of current opioids. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. Otherwise, the goal of one study is to demonstrate current computational capabilities to predict drug bio distribution while varying three parameters. Comparison between the idealized spine computations and bench-top tracer distribution experiments demonstrate agreement of our drug transport predictions to this physical model [6] .
They are selected due to the availability of pharmacological drug-molecule binding data for these receptors. Feedback and deep belief artificial neural network architectures (NNs) were chosen to perform the task of aiding drug design. This is done by training on structural features, selected using a "minimum redundancy, maximum relevance"-test, and testing for successful prediction of categorized binding strength. An extensive comparison of the neural network performances was made in order to select the optimal architecture. Deep belief networks, trained with greedy learning algorithms, showed superior performance in prediction over the simple feedback NNs. The best networks obtained scores of more than 90 % accuracy in predicting the degree of binding drug molecules to the mentioned receptors. After training the networks, tests were done on how well the systems could be used as an aid in designing candidate drug molecules [2, 7] . These ligand characteristics could be total number of atoms, their types etc. Principal component analysis of the movements of the receptor transmembrane domains showed that the buprenorphine-bound receptor occupied a distinct set of conformations to the norbuprenorphine-bound receptor. Addition of an allosteric sodium ion caused the receptor and ligand to adopt an inactive conformation. The differences in ligandresidue interactions and receptor conformations observed here may underlie the differing efficacies for cellular signaling outputs for these ligands.
